<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.0 20040830//EN" "http://dtd.nlm.nih.gov/publishing/2.0/journalpublishing.dtd">
<article article-type="letter" dtd-version="2.0" xmlns:xlink="http://www.w3.org/1999/xlink">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">JMIR</journal-id>
      <journal-id journal-id-type="nlm-ta">JMIR AI</journal-id>
      <journal-title>JMIR AI</journal-title>
      <issn pub-type="epub">2817-1705</issn>
      <publisher>
        <publisher-name>JMIR Publications</publisher-name>
        <publisher-loc>Toronto, Canada</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">v5i1e83413</article-id>
      <article-id pub-id-type="pmid">37309177</article-id>
      <article-id pub-id-type="doi">10.2196/83413</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Letter</subject>
        </subj-group>
        <subj-group subj-group-type="article-type">
          <subject>Research Letter</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Primary Health Conditions Among Medical Crowdfunding Campaigns in the United States: Natural Language Processing Study</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="editor">
          <name>
            <surname>Yin</surname>
            <given-names>Zhijun</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="reviewer">
          <name>
            <surname>Chrimes</surname>
            <given-names>Dillon</given-names>
          </name>
        </contrib>
        <contrib contrib-type="reviewer">
          <name>
            <surname>García-Barragán</surname>
            <given-names>Álvaro</given-names>
          </name>
        </contrib>
        <contrib contrib-type="reviewer">
          <name>
            <surname>Fan</surname>
            <given-names>Jungwei</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib id="contrib1" contrib-type="author">
          <name name-style="western">
            <surname>Yu</surname>
            <given-names>Shaojun</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref rid="aff1" ref-type="aff">1</xref>
          <xref rid="aff2" ref-type="aff">2</xref>
          <ext-link ext-link-type="orcid">https://orcid.org/0000-0003-3938-5828</ext-link>
        </contrib>
        <contrib id="contrib2" contrib-type="author">
          <name name-style="western">
            <surname>Liu</surname>
            <given-names>Shu</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref rid="aff1" ref-type="aff">1</xref>
          <ext-link ext-link-type="orcid">https://orcid.org/0009-0005-4838-7763</ext-link>
        </contrib>
        <contrib id="contrib3" contrib-type="author">
          <name name-style="western">
            <surname>Yabroff</surname>
            <given-names>K Robin</given-names>
          </name>
          <degrees>MBA, PhD</degrees>
          <xref rid="aff1" ref-type="aff">1</xref>
          <ext-link ext-link-type="orcid">https://orcid.org/0000-0003-0644-5572</ext-link>
        </contrib>
        <contrib id="contrib4" contrib-type="author">
          <name name-style="western">
            <surname>Islami</surname>
            <given-names>Farhad</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref rid="aff1" ref-type="aff">1</xref>
          <ext-link ext-link-type="orcid">https://orcid.org/0000-0002-7357-5994</ext-link>
        </contrib>
        <contrib id="contrib5" contrib-type="author">
          <name name-style="western">
            <surname>Chino</surname>
            <given-names>Fumiko</given-names>
          </name>
          <degrees>MD</degrees>
          <xref rid="aff3" ref-type="aff">3</xref>
          <ext-link ext-link-type="orcid">https://orcid.org/0000-0003-0498-488X</ext-link>
        </contrib>
        <contrib id="contrib6" contrib-type="author">
          <name name-style="western">
            <surname>Zhang</surname>
            <given-names>Jing</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref rid="aff2" ref-type="aff">2</xref>
          <ext-link ext-link-type="orcid">https://orcid.org/0009-0000-4084-2112</ext-link>
        </contrib>
        <contrib id="contrib7" contrib-type="author" corresp="yes">
          <name name-style="western">
            <surname>Zheng</surname>
            <given-names>Zhiyuan</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref rid="aff1" ref-type="aff">1</xref>
          <address>
            <institution>Surveillance, Prevention &amp; Health Services Research Department</institution>
            <institution>American Cancer Society</institution>
            <addr-line>270 Peachtree Street NW Suite 1300</addr-line>
            <addr-line>Atlanta, GA, 30303</addr-line>
            <country>United States</country>
            <phone>1 4044175985</phone>
            <email>jason.zheng@cancer.org</email>
          </address>
          <ext-link ext-link-type="orcid">https://orcid.org/0000-0002-7665-3564</ext-link>
        </contrib>
      </contrib-group>
      <aff id="aff1">
        <label>1</label>
        <institution>Surveillance, Prevention &amp; Health Services Research Department</institution>
        <institution>American Cancer Society</institution>
        <addr-line>Atlanta, GA</addr-line>
        <country>United States</country>
      </aff>
      <aff id="aff2">
        <label>2</label>
        <institution>Computer Science Department</institution>
        <institution>Emory University</institution>
        <addr-line>Atlanta, GA</addr-line>
        <country>United States</country>
      </aff>
      <aff id="aff3">
        <label>3</label>
        <institution>Department of Breast Radiation Oncology</institution>
        <institution>MD Anderson Cancer Center</institution>
        <addr-line>Houston, TX</addr-line>
        <country>United States</country>
      </aff>
      <author-notes>
        <corresp>Corresponding Author: Zhiyuan Zheng <email>jason.zheng@cancer.org</email></corresp>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2026</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>17</day>
        <month>4</month>
        <year>2026</year>
      </pub-date>
      <volume>5</volume>
      <elocation-id>e83413</elocation-id>
      <history>
        <date date-type="received">
          <day>2</day>
          <month>9</month>
          <year>2025</year>
        </date>
        <date date-type="rev-request">
          <day>24</day>
          <month>11</month>
          <year>2025</year>
        </date>
        <date date-type="rev-recd">
          <day>4</day>
          <month>2</month>
          <year>2026</year>
        </date>
        <date date-type="accepted">
          <day>16</day>
          <month>3</month>
          <year>2026</year>
        </date>
      </history>
      <copyright-statement>©Shaojun Yu, Shu Liu, K Robin Yabroff, Farhad Islami, Fumiko Chino, Jing Zhang, Zhiyuan Zheng. Originally published in JMIR AI (https://ai.jmir.org), 17.04.2026.</copyright-statement>
      <copyright-year>2026</copyright-year>
      <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/">
        <p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR AI, is properly cited. The complete bibliographic information, a link to the original publication on https://www.ai.jmir.org/, as well as this copyright and license information must be included.</p>
      </license>
      <self-uri xlink:href="https://ai.jmir.org/2026/1/e83413" xlink:type="simple"/>
      <kwd-group>
        <kwd>medical crowdfunding</kwd>
        <kwd>primary health conditions</kwd>
        <kwd>natural language processing</kwd>
        <kwd>crowdfunding economy</kwd>
        <kwd>major health conditions</kwd>
        <kwd>funds received and requested</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="introduction">
      <title>Introduction</title>
      <p>Average US health care spending accounted for 20.4% of annual per capita income ($13,493 of $66,220; all monetary values are in US $) in 2022 [<xref ref-type="bibr" rid="ref1">1</xref>]. Moreover, many Americans have limited liquid assets for unexpected out-of-pocket medical costs [<xref ref-type="bibr" rid="ref2">2</xref>]. Therefore, peer-to-peer medical crowdfunding campaigns are increasingly used to raise money for medical expenses [<xref ref-type="bibr" rid="ref3">3</xref>]. However, little evidence is available about which health conditions are driving increases in crowdfunding campaigns and the magnitude of unmet financial needs.</p>
      <p>Manual review of crowdfunding campaigns is not feasible at scale. This study used a large natural language processing (NLP) model to empirically categorize US medical crowdfunding campaigns by primary health condition and to quantify funds requested, funds received, and resulting shortfalls between funds requested and received. The aim of this study was to identify the major health conditions driving medical crowdfunding and to characterize variation in fundraising outcomes across conditions.</p>
    </sec>
    <sec sec-type="methods">
      <title>Methods</title>
      <sec>
        <title>Overview</title>
        <p>A web scraper was manually developed in Python using standard HTML parsing techniques to systematically retrieve publicly available crowdfunding campaigns categorized as “medical” on the GoFundMe website and initiated between May 1, 2022, and May 31, 2023 [<xref ref-type="bibr" rid="ref4">4</xref>]. Each campaign webpage includes a unique ID, the primary fundraising narrative, and donation records. Donation records were collected for 90 days, when most campaign activity occurs. The main fundraising stories typically describe the beneficiary’s health condition and specific needs. All campaigns were limited to those originating in the United States and written in English. All stories were preprocessed to remove special characters, emojis, and formatting artifacts before NLP classification.</p>
        <p>An empirical multistage NLP approach was developed to categorize campaigns by health condition. A large language model (LLM; GPT-3.5 [OpenAI]; about 4000 words per query) was used to analyze fundraising stories, and for each campaign, the LLM was instructed to identify a single primary health condition most directly related to the fundraising purpose (<xref rid="figure1" ref-type="fig">Figure 1</xref>). As GPT-3.5 is most efficient in grouping tasks when analyzing 500 to 1500 words, we sequentially divided all campaigns into smaller groups, with 1000 in each group. The same NLP model was used to obtain the top 10 most mentioned health conditions from each small group. Because fundraising stories use diverse and nonstandard descriptions of health conditions, which are typically not consistent with standardized taxonomies such as the <italic>International Classification of Diseases, 10th Revision</italic> (<italic>ICD-10</italic>), we manually consolidated related terms into broader disease categories to improve interpretability and consistency. The most common 20 categories (19 conditions plus “others”; keywords for each condition are shown in the table below) were selected based on the number of times that condition appeared on the list of 1230 health conditions. We followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline for all summary statistics [<xref ref-type="bibr" rid="ref5">5</xref>].</p>
        <fig id="figure1" position="float">
          <label>Figure 1</label>
          <caption>
            <p>Diagram of the empirical approach used to extract primary health conditions from US medical crowdfunding campaigns.</p>
          </caption>
          <graphic xlink:href="ai_v5i1e83413_fig1.png" alt-version="no" mimetype="image" position="float" xlink:type="simple"/>
        </fig>
      </sec>
      <sec>
        <title>Ethical Considerations</title>
        <p>This study was deemed exempt from ethical approval by the Morehouse School of Medicine Institutional Review Board.</p>
      </sec>
    </sec>
    <sec sec-type="results">
      <title>Results</title>
      <p>In total, 122,682 medical crowdfunding campaigns were identified (<xref ref-type="table" rid="table1">Table 1</xref>). Cancer was the leading health condition by volume (n=51,843, 42.3% of all campaigns), followed by injury-related conditions (n=10,423, 8.5%), heart-related disease (n=8659, 7.1%), and neurological disease (n=6248, 5.1%).</p>
      <table-wrap position="float" id="table1">
        <label>Table 1</label>
        <caption>
          <p>Funds requested and received by health condition among medical crowdfunding campaigns in the United States. All medical crowdfunding campaigns were retrieved from the publicly available GoFundMe website that were initiated between May 1, 2022, and May 31, 2023, and followed up with 90 days of donation records.</p>
        </caption>
        <table width="1000" cellpadding="5" cellspacing="0" border="1" rules="groups" frame="hsides">
          <col width="90"/>
          <col width="90"/>
          <col width="90"/>
          <col width="170"/>
          <col width="70"/>
          <col width="90"/>
          <col width="120"/>
          <col width="100"/>
          <col width="80"/>
          <col width="100"/>
          <thead>
            <tr valign="bottom">
              <td>Health conditions</td>
              <td>Crowdfunding campaigns, n (%)</td>
              <td>Campaigns with funds requested and received, n<sup>a</sup></td>
              <td>Total amount of funds requested<sup>b</sup> vs received<sup>c</sup> (US $), n/N (%)</td>
              <td>Funds received per campaign (US $), mean (SD)</td>
              <td>Funds requested per campaign (US $), mean (SD)</td>
              <td>Median funds requested per campaign (US $), median, (IQR)</td>
              <td>Median funds received per campaign (US $), median, (IQR)</td>
              <td>All campaigns reaching fundraising goals (%)<sup>b,c</sup></td>
              <td>Campaigns reaching fundraising goals that received &gt;US $50,000) (%)<sup>b,c</sup></td>
            </tr>
          </thead>
          <tbody>
            <tr valign="top">
              <td>All health conditions</td>
              <td>122,682 (100.0)</td>
              <td>112,198</td>
              <td>1,871,526,583/575,914,886 (30.8)</td>
              <td>5133 (8880)</td>
              <td>16,681 (22,692)</td>
              <td>10,000 (5000-20,000)</td>
              <td>2207 (860-5730)</td>
              <td>10,214 (9.2)</td>
              <td>755 (0.68)</td>
            </tr>
            <tr valign="top">
              <td>Cancer</td>
              <td>51,843 (42.3)</td>
              <td>48,871</td>
              <td>889,109,288/273,959,992 (30.8)</td>
              <td>5606 (8044)</td>
              <td>18,192 (21,660)</td>
              <td>10,000 (5000-20,000)</td>
              <td>2880 (1130-6990)</td>
              <td>4,072 (8.4)</td>
              <td>260 (0.53)</td>
            </tr>
            <tr valign="top">
              <td>Injury-related conditions<sup>d</sup></td>
              <td>10,423 (8.5)</td>
              <td>9564</td>
              <td>191,429,273/59,966,728 (31.3)</td>
              <td>6270 (13,407)</td>
              <td>20,015 (32,019)</td>
              <td>10,000 (5000-20,000)</td>
              <td>2060 (810-5722)</td>
              <td>939 (9.8)</td>
              <td>186 (1.94)</td>
            </tr>
            <tr valign="top">
              <td>Heart-related diseases</td>
              <td>8659 (7.1)</td>
              <td>8027</td>
              <td>123,384,193/37,895,760 (30.7)</td>
              <td>4721 (8512)</td>
              <td>15,371 (20,836)</td>
              <td>10,000 (5000-18,000)</td>
              <td>1954 (795-5004)</td>
              <td>827 (10.3)</td>
              <td>51 (0.64)</td>
            </tr>
            <tr valign="top">
              <td>Neurological diseases<sup>e</sup></td>
              <td>6248 (5.1)</td>
              <td>5380</td>
              <td>97,947,309/32,332,547 (33.0)</td>
              <td>6010 (11,856)</td>
              <td>18,206 (26,590)</td>
              <td>10,000 (5000-20,000)</td>
              <td>2186 (835-6012)</td>
              <td>634 (11.8)</td>
              <td>74 (1.38)</td>
            </tr>
            <tr valign="top">
              <td>Stroke</td>
              <td>5360 (4.4)</td>
              <td>4902</td>
              <td>93,430,952/29,217,036 (31.3)</td>
              <td>5960 (10,883)</td>
              <td>19,060 (26,170)</td>
              <td>10,000 (5000-20,000)</td>
              <td>2462 (970-6434)</td>
              <td>467 (9.5)</td>
              <td>56 (1.14)</td>
            </tr>
            <tr valign="top">
              <td>Infectious diseases</td>
              <td>4540 (3.7)</td>
              <td>4149</td>
              <td>54,009,867/17,758,936 (32.8)</td>
              <td>4280 (7640)</td>
              <td>13,018 (17,880)</td>
              <td>6607 (3500-15,000)</td>
              <td>1783 (710-4525)</td>
              <td>437 (10.5)</td>
              <td>28 (0.67)</td>
            </tr>
            <tr valign="top">
              <td>Kidney-related diseases</td>
              <td>4027 (3.3)</td>
              <td>3698</td>
              <td>55,918,536/14,109,460 (25.2)</td>
              <td>3815 (7213)</td>
              <td>15,121 (21,880)</td>
              <td>8000 (4000-18,000)</td>
              <td>1600 (655-3950)</td>
              <td>329 (8.9)</td>
              <td>18 (0.49)</td>
            </tr>
            <tr valign="top">
              <td>Pain-related and musculoskeletal disorders<sup>f</sup></td>
              <td>3950 (3.2)</td>
              <td>3429</td>
              <td>43,462,058/11,993,688 (27.6)</td>
              <td>3498 (6588)</td>
              <td>12,675 (17,387)</td>
              <td>7000 (3500-15,000)</td>
              <td>1440 (615-3700)</td>
              <td>376 (11.0)</td>
              <td>12 (0.35)</td>
            </tr>
            <tr valign="top">
              <td>Lung-related diseases<sup>g</sup></td>
              <td>3090 (2.5)</td>
              <td>2855</td>
              <td>37,071,628 /12,351,260 (33.3)</td>
              <td>4326 (7767)</td>
              <td>12,985 (17,943)</td>
              <td>6000 (3500-15,000)</td>
              <td>1790 (767-4432)</td>
              <td>358 (12.5)</td>
              <td>16 (0.56)</td>
            </tr>
            <tr valign="top">
              <td>Genetic-related diseases<sup>h</sup></td>
              <td>2868 (2.3)</td>
              <td>2428</td>
              <td>42,152,956/12,173,939 (28.8)</td>
              <td>5014 (8650)</td>
              <td>17,361 (28,849)</td>
              <td>9032 (4000-20,000)</td>
              <td>2080 (865-5171)</td>
              <td>310 (12.8)</td>
              <td>15 (0.62)</td>
            </tr>
            <tr valign="top">
              <td>Autoimmune-related diseases<sup>i</sup></td>
              <td>2379 (1.9)</td>
              <td>2140</td>
              <td>29,812,924/8,870,851 (29.8)</td>
              <td>4145 (6791)</td>
              <td>13,931 (18,840)</td>
              <td>7500 (4000-15,000)</td>
              <td>1877 (750-4503)</td>
              <td>241 (11.3)</td>
              <td>5 (0.23)</td>
            </tr>
            <tr valign="top">
              <td>Liver-related diseases</td>
              <td>2079 (1.7)</td>
              <td>1934</td>
              <td>36,243,923/8,888,493 (24.5)</td>
              <td>4596 (7647)</td>
              <td>18,740 (30,296)</td>
              <td>10,000 (5000-20,000)</td>
              <td>2009 (840-5024)</td>
              <td>173 (8.9)</td>
              <td>7 (0.36)</td>
            </tr>
            <tr valign="top">
              <td>Diabetes</td>
              <td>1971 (1.6)</td>
              <td>1840</td>
              <td>22,875,850/5,527,402 (24.2)</td>
              <td>3004 (5471)</td>
              <td>12,433 (17,823)</td>
              <td>7000 (3500-14,000)</td>
              <td>1290 (590-3123)</td>
              <td>143 (7.8)</td>
              <td>4 (0.21)</td>
            </tr>
            <tr valign="top">
              <td>Mental illnesses<sup>j</sup></td>
              <td>1543 (1.3)</td>
              <td>1263</td>
              <td>14,448,719/4,573,398 (31.6)</td>
              <td>3621 (6387)</td>
              <td>11,440 (14,259)</td>
              <td>6000 (3000-14,000)</td>
              <td>1420 (555-3877)</td>
              <td>142 (11.3)</td>
              <td>4 (0.32)</td>
            </tr>
            <tr valign="top">
              <td>COVID-19</td>
              <td>1118 (0.9)</td>
              <td>1007</td>
              <td>13,909,965/4,547,831 (32.7)</td>
              <td>4516 (8591)</td>
              <td>13,813 (18,508)</td>
              <td>7500 (3463-15,000)</td>
              <td>1815 (756-4305)</td>
              <td>117 (11.6)</td>
              <td>6 (0.60)</td>
            </tr>
            <tr valign="top">
              <td>Epilepsy</td>
              <td>977 (0.8)</td>
              <td>836</td>
              <td>10,571,567/3,201,893 (30.3)</td>
              <td>3830 (6256)</td>
              <td>12,645 (16,904)</td>
              <td>7000 (3000-15,000)</td>
              <td>1670 (664-4501)</td>
              <td>104 (12.5)</td>
              <td>3 (0.36)</td>
            </tr>
            <tr valign="top">
              <td>Multiple sclerosis</td>
              <td>806 (0.7)</td>
              <td>659</td>
              <td>9,947,287/3,170,741 (31.8)</td>
              <td>4811 (8818)</td>
              <td>15,095 (18,540)</td>
              <td>10,000 (4000-16,000)</td>
              <td>1920 (840-5205)</td>
              <td>74 (11.3)</td>
              <td>4 (0.61)</td>
            </tr>
            <tr valign="top">
              <td>Autism</td>
              <td>552 (0.4)</td>
              <td>440</td>
              <td>4,937,909/1,491,344 (30.2)</td>
              <td>3389 (6528)</td>
              <td>11,223 (14,275)</td>
              <td>6000 (3000-15,000)</td>
              <td>1407 (570-3096)</td>
              <td>50 (11.4)</td>
              <td>2 (0.45)</td>
            </tr>
            <tr valign="top">
              <td>Alzheimer disease</td>
              <td>501 (0.4)</td>
              <td>386</td>
              <td>7,087,213/2,388,499 (33.7)</td>
              <td>6188 (13,656)</td>
              <td>18,361 (25,238)</td>
              <td>10,000 (5000-20,000)</td>
              <td>1972 (827-5327)</td>
              <td>41 (10.7)</td>
              <td>6 (1.55)</td>
            </tr>
            <tr valign="top">
              <td>Others</td>
              <td>9748 (7.9)</td>
              <td>8390</td>
              <td>1,871,526,583/575,914,886 (33.5)</td>
              <td>3754 (7,390)</td>
              <td>11,177 (15,410)</td>
              <td>5200 (3000-10,000)</td>
              <td>1455 (580-3864)</td>
              <td>1,059 (12.7)</td>
              <td>43 (0.51)</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="table1fn1">
            <p><sup>a</sup>Crowdfunding campaigns without fundraising goals or without any donations were excluded.</p>
          </fn>
          <fn id="table1fn2">
            <p><sup>b</sup>The calculation of funds requested (ie, fundraising goals) excluded missing values and those &lt;1st percentile and &gt;99th percentile.</p>
          </fn>
          <fn id="table1fn3">
            <p><sup>c</sup>For campaigns for which the funds received reached or exceeded fundraising goals, percentages were capped at 100% (ie, all those &gt;1 were set as 100%).</p>
          </fn>
          <fn id="table1fn4">
            <p><sup>d</sup>Injury-related conditions included the following terms: <italic>accidents</italic>, <italic>injuries</italic>, <italic>trauma</italic>, <italic>fractures</italic>, and <italic>amputations</italic>.</p>
          </fn>
          <fn id="table1fn5">
            <p><sup>e</sup>Neurological-related diseases included the following terms: <italic>neurological disorders</italic>, <italic>neurological conditions</italic>, and <italic>cerebral palsy</italic>.</p>
          </fn>
          <fn id="table1fn6">
            <p><sup>f</sup>Pain-related and musculoskeletal disorders included the following terms: pain, chronic pain, chronic pain syndromes, osteoarthritis, musculoskeletal, and muscular dystrophy.</p>
          </fn>
          <fn id="table1fn7">
            <p><sup>g</sup>Lung-related diseases included the following terms: <italic>respiratory diseases</italic>, <italic>respiratory issues</italic>, <italic>lung diseases</italic>, <italic>COPD</italic>, <italic>pneumonia</italic>, and <italic>pulmonary fibrosis</italic>.</p>
          </fn>
          <fn id="table1fn8">
            <p><sup>h</sup>Genetic-related diseases included the following terms: <italic>genetic diseases</italic>, <italic>genetic disorders</italic>, <italic>Ehlers-Danlos syndrome</italic>, <italic>Down syndrome</italic>, and <italic>Crouzon syndrome</italic>.</p>
          </fn>
          <fn id="table1fn9">
            <p><sup>i</sup>Autoimmune-related diseases included the following terms: <italic>autoimmune diseases</italic>, <italic>autoimmune disorders</italic>, <italic>lupus</italic>, and <italic>rheumatoid</italic>.</p>
          </fn>
          <fn id="table1fn10">
            <p><sup>j</sup>Mental illnesses included the following terms: <italic>mental illnesses</italic> and <italic>mental health</italic>.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>The majority (n=112,198, 91.5%) of campaigns listed fundraising goals and received donations; among which, the total amount received ($575,914,886) accounted for 30.8% of the total funds requested ($1,871,526,583). Only 9.2% achieved their fundraising goals within 90 days after campaign initiation.</p>
      <p>Cancer-related campaigns received the highest amounts of financial assistance (median $2880, IQR $1130-$6990 per campaign), followed by stroke ($2462, IQR $970-$6434), neurological diseases ($2186, IQR $835-$6012), and injury-related conditions ($2060, IQR $810-$5772), whereas diabetes received the lowest amounts (median: $1290, IQR $590-$3123). Alzheimer’s disease had the highest proportion of funds received relative to funds requested (33.7%), driven by a relatively higher share of campaigns that raised ≥$50,000 (1.55%).</p>
      <p>Manual review of 500 randomly selected crowdfunding stories showed condition classification accuracy of 92.3%, consistent with previous literature [<xref ref-type="bibr" rid="ref3">3</xref>].</p>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>In this contemporary analysis of more than 100,000 US medical crowdfunding campaigns over a 13-month period, we identified the 20 most common categories, which collectively raised $575,914,886 during the 90-day follow-up. The frequency at which health conditions were mentioned in crowdfunding campaigns does not reflect their prevalence at the population level, but instead aspects of financial hardship due to the condition [<xref ref-type="bibr" rid="ref6">6</xref>]. As such, the total funds requested and the proportion actually received varied greatly by health condition, with the median cancer crowdfunding campaign raising more than twice as much as that for diabetes.</p>
      <p>Cancer-related crowdfunding campaigns also represent nearly the combined number of campaigns of all other 18 common health conditions. Moreover, cancer-related campaigns received the most donations but, due to higher fundraising goals, these campaigns raised proportionately less of the requested total [<xref ref-type="bibr" rid="ref7">7</xref>]. Previous research showed that cancer-related crowdfunding campaigns are often initiated due to high out-of-pocket medical costs and unmet social needs (ie, food, housing, and transportation), as patients experience disruptions in employment, insurance, and income following diagnosis [<xref ref-type="bibr" rid="ref3">3</xref>,<xref ref-type="bibr" rid="ref8">8</xref>]. Moreover, campaign success depends on social networks, visibility, and donors’ capacity to give—factors that vary by socioeconomic status and geography and may potentially widen disparities in access to cancer care [<xref ref-type="bibr" rid="ref9">9</xref>].</p>
      <p>A limitation of this study is that health conditions identified through NLP analyses cannot be verified by medical records. Although standardized taxonomies such as <italic>ICD-10</italic> provide well-established disease classifications, they are rarely mentioned in fundraising stories written by patients and informal caregivers. Our empirical approach focused on how health conditions were described in crowdfunding stories, which may not map cleanly to <italic>ICD-10</italic> codes nor capture multiple conditions; future work could explore systematic mappings to improve comparability. At the time this study was conducted, GPT-3.5 was the available LLM and was therefore used; subsequent advances in LLM availability may allow future studies to conduct similar large-scale analyses using different LLMs. Because this study examined only GoFundMe campaigns, the findings may reflect platform-specific dynamics and may not be generalizable to other crowdfunding platforms. The proportion of funds received relative to requested amounts reflects relative unmet need, whereas total requested amounts represent absolute financial burden. Accordingly, low goal attainment should not be interpreted as inefficiency or failure of crowdfunding. The observed shortfalls underscore persistent financial challenges faced by patients and families and highlight the need for further research and policy attention.</p>
    </sec>
  </body>
  <back>
    <app-group/>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term id="abb1">ICD-10</term>
          <def>
            <p>International Classification of Diseases, 10th Revision</p>
          </def>
        </def-item>
        <def-item>
          <term id="abb2">LLM</term>
          <def>
            <p>large language model</p>
          </def>
        </def-item>
        <def-item>
          <term id="abb3">NLP</term>
          <def>
            <p>natural language processing</p>
          </def>
        </def-item>
        <def-item>
          <term id="abb4">STROBE</term>
          <def>
            <p>Strengthening the Reporting of Observational Studies in Epidemiology</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <notes>
      <title>Data Availability</title>
      <p>The data analyzed in this manuscript are publicly available from the GoFundMe website [<xref ref-type="bibr" rid="ref4">4</xref>].</p>
    </notes>
    <notes>
      <title>Funding</title>
      <p>No funding was received for this work.</p>
    </notes>
    <fn-group>
      <fn fn-type="con">
        <p>SY, SL, and ZZ had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: SY, ZZ, and KRY. Acquisition, analysis, or interpretation of data: SY, SL, and ZZ. Drafting of the manuscript: SY, ZZ, and KRY. Critical revision of the manuscript for important intellectual content: all authors.</p>
      </fn>
      <fn fn-type="conflict">
        <p>FC is supported by a National Institutes of Health/National Cancer Institute Cancer Center support grant (P30 CA008748). ZZ, SL, FI, and RKY are employed by the American Cancer Society, a not-for-profit public health organization that receives support from the public through fundraising and direct contributions. The society also receives a small portion of support from corporations and industry to support its mission programs and services. No other disclosures are reported.</p>
      </fn>
    </fn-group>
    <ref-list>
      <ref id="ref1">
        <label>1</label>
        <nlm-citation citation-type="web">
          <article-title>National health expenditure fact sheet</article-title>
          <source>U.S. Centers for Medicare and Medicaid Services</source>
          <access-date>2026-03-19</access-date>
          <comment>
            <ext-link ext-link-type="uri" xlink:type="simple" xlink:href="https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data/nhe-fact-sheet">https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data/nhe-fact-sheet</ext-link>
          </comment>
        </nlm-citation>
      </ref>
      <ref id="ref2">
        <label>2</label>
        <nlm-citation citation-type="web">
          <article-title>Economic well-being of U.S. households in 2022</article-title>
          <source>Federal Reserve</source>
          <year>2023</year>
          <month>5</month>
          <access-date>2026-03-19</access-date>
          <comment>
            <ext-link ext-link-type="uri" xlink:type="simple" xlink:href="https://www.federalreserve.gov/publications/files/2022-report-economic-well-being-us-households-202305.pdf">https://www.federalreserve.gov/publications/files/2022-report-economic-well-being-us-households-202305.pdf</ext-link>
          </comment>
        </nlm-citation>
      </ref>
      <ref id="ref3">
        <label>3</label>
        <nlm-citation citation-type="journal">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Zheng</surname>
              <given-names>Z</given-names>
            </name>
            <name name-style="western">
              <surname>Yu</surname>
              <given-names>S</given-names>
            </name>
            <name name-style="western">
              <surname>Islami</surname>
              <given-names>F</given-names>
            </name>
            <name name-style="western">
              <surname>Banegas</surname>
              <given-names>MP</given-names>
            </name>
            <name name-style="western">
              <surname>Zhao</surname>
              <given-names>J</given-names>
            </name>
            <name name-style="western">
              <surname>Zhang</surname>
              <given-names>J</given-names>
            </name>
            <name name-style="western">
              <surname>Chino</surname>
              <given-names>F</given-names>
            </name>
            <name name-style="western">
              <surname>Yabroff</surname>
              <given-names>KR</given-names>
            </name>
          </person-group>
          <article-title>Natural language processing-assessed unmet medical and social needs in cancer crowdfunding stories</article-title>
          <source>JAMA Oncol</source>
          <year>2024</year>
          <month>10</month>
          <day>10</day>
          <volume>10</volume>
          <issue>12</issue>
          <fpage>1726</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1001/jamaoncol.2024.4412</pub-id>
          <pub-id pub-id-type="medline">39388155</pub-id>
          <pub-id pub-id-type="pii">2824840</pub-id>
          <pub-id pub-id-type="pmcid">PMC11581532</pub-id>
        </nlm-citation>
      </ref>
      <ref id="ref4">
        <label>4</label>
        <nlm-citation citation-type="web">
          <article-title>Discover medical fundraisers on GoFundMe</article-title>
          <source>GoFundMe</source>
          <access-date>2026-03-19</access-date>
          <comment>
            <ext-link ext-link-type="uri" xlink:type="simple" xlink:href="https://www.gofundme.com/discover/medical-fundraiser">https://www.gofundme.com/discover/medical-fundraiser</ext-link>
          </comment>
        </nlm-citation>
      </ref>
      <ref id="ref5">
        <label>5</label>
        <nlm-citation citation-type="web">
          <article-title>The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies</article-title>
          <source>Equator Network</source>
          <access-date>2026-03-19</access-date>
          <comment>
            <ext-link ext-link-type="uri" xlink:type="simple" xlink:href="https://www.equator-network.org/reporting-guidelines/strobe/">https://www.equator-network.org/reporting-guidelines/strobe/</ext-link>
          </comment>
        </nlm-citation>
      </ref>
      <ref id="ref6">
        <label>6</label>
        <nlm-citation citation-type="web">
          <article-title>Fast facts: health and economic costs of chronic conditions</article-title>
          <source>U.S. Centers for Disease Control and Prevention</source>
          <access-date>2026-03-19</access-date>
          <comment>
            <ext-link ext-link-type="uri" xlink:type="simple" xlink:href="https://www.cdc.gov/chronic-disease/data-research/facts-stats/index.html">https://www.cdc.gov/chronic-disease/data-research/facts-stats/index.html</ext-link>
          </comment>
        </nlm-citation>
      </ref>
      <ref id="ref7">
        <label>7</label>
        <nlm-citation citation-type="journal">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Dusetzina</surname>
              <given-names>SB</given-names>
            </name>
            <name name-style="western">
              <surname>Huskamp</surname>
              <given-names>HA</given-names>
            </name>
            <name name-style="western">
              <surname>Keating</surname>
              <given-names>NL</given-names>
            </name>
          </person-group>
          <article-title>Specialty drug pricing and out-of-pocket spending on orally administered anticancer drugs in Medicare Part D, 2010 to 2019</article-title>
          <source>JAMA</source>
          <year>2019</year>
          <month>05</month>
          <day>28</day>
          <volume>321</volume>
          <issue>20</issue>
          <fpage>2025</fpage>
          <lpage>2027</lpage>
          <comment>
            <ext-link ext-link-type="uri" xlink:type="simple" xlink:href="https://europepmc.org/abstract/MED/31135837"/>
          </comment>
          <pub-id pub-id-type="doi">10.1001/jama.2019.4492</pub-id>
          <pub-id pub-id-type="medline">31135837</pub-id>
          <pub-id pub-id-type="pii">2734308</pub-id>
          <pub-id pub-id-type="pmcid">PMC6547115</pub-id>
        </nlm-citation>
      </ref>
      <ref id="ref8">
        <label>8</label>
        <nlm-citation citation-type="journal">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Zheng</surname>
              <given-names>Z</given-names>
            </name>
            <name name-style="western">
              <surname>Yu</surname>
              <given-names>Shaojun</given-names>
            </name>
            <name name-style="western">
              <surname>Chino</surname>
              <given-names>Fumiko</given-names>
            </name>
            <name name-style="western">
              <surname>Islami</surname>
              <given-names>Farhad</given-names>
            </name>
            <name name-style="western">
              <surname>Zhao</surname>
              <given-names>Jingxuan</given-names>
            </name>
            <name name-style="western">
              <surname>Banegas</surname>
              <given-names>Matthew P</given-names>
            </name>
            <name name-style="western">
              <surname>An</surname>
              <given-names>Zhenan</given-names>
            </name>
            <name name-style="western">
              <surname>Zhang</surname>
              <given-names>Jing</given-names>
            </name>
            <name name-style="western">
              <surname>Yabroff</surname>
              <given-names>K Robin</given-names>
            </name>
          </person-group>
          <article-title>Cancer-related crowdfunding economy in the United States</article-title>
          <source>J Natl Compr Canc Netw</source>
          <year>2025</year>
          <month>11</month>
          <volume>23</volume>
          <issue>11</issue>
          <fpage>e257069</fpage>
          <pub-id pub-id-type="doi">10.6004/jnccn.2025.7069</pub-id>
          <pub-id pub-id-type="medline">41213243</pub-id>
          <pub-id pub-id-type="pii">e257069</pub-id>
        </nlm-citation>
      </ref>
      <ref id="ref9">
        <label>9</label>
        <nlm-citation citation-type="journal">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Davis</surname>
              <given-names>AR</given-names>
            </name>
            <name name-style="western">
              <surname>Elbers</surname>
              <given-names>SK</given-names>
            </name>
            <name name-style="western">
              <surname>Kenworthy</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Racial and gender disparities among highly successful medical crowdfunding campaigns</article-title>
          <source>Soc Sci Med</source>
          <year>2023</year>
          <month>05</month>
          <volume>324</volume>
          <fpage>115852</fpage>
          <comment>
            <ext-link ext-link-type="uri" xlink:type="simple" xlink:href="https://europepmc.org/abstract/MED/36989837"/>
          </comment>
          <pub-id pub-id-type="doi">10.1016/j.socscimed.2023.115852</pub-id>
          <pub-id pub-id-type="medline">36989837</pub-id>
          <pub-id pub-id-type="pii">S0277-9536(23)00209-5</pub-id>
          <pub-id pub-id-type="pmcid">PMC10916987</pub-id>
        </nlm-citation>
      </ref>
    </ref-list>
  </back>
</article>
